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Abstract: (1) Background: This study evaluated the perioperative red blood cell (RBC) transfusion
need and determined predictors for transfusion in patients undergoing elective primary lumbar
posterior spine fusion in a high-volume center for spine surgery. (2) Methods: Data from all patients
undergoing spine surgery between 1 January 2014 and 31 December 2016 were reviewed. Patients’
demographics and comorbidities, perioperative laboratory results, and operative time were analyzed
in relation to RBC transfusion. Multivariate logistic regression analysis was performed to identify
the predictors of transfusion. (3) Results: A total of 874 elective surgeries for primary spine fusion
were performed over the three years. Only 54 cases (6%) required RBC transfusion. Compared
to the non-transfused patients, transfused patients were mainly female (p = 0.0008), significantly
older, with a higher ASA grade (p = 0.0002), and with lower pre-surgery hemoglobin (HB) level and
hematocrit (p < 0.0001). In the multivariate logistic regression, a lower pre-surgery HB (OR (95% CI)
2.84 (2.11–3.82)), a higher ASA class (1.77 (1.03–3.05)) and a longer operative time (1.02 (1.01–1.02))
were independently associated with RBC transfusion. (4) Conclusions: In the instance of elective
surgery for primary posterior lumbar fusion in a high-volume center for spine surgery, the need for
RBC transfusion is low. Factors anticipating transfusion should be taken into consideration in the
patient’s pre-surgery preparation.
Keywords: blood; blood loss; spine surgery; spine fusion; lumbar; transfusion; red blood cell;
hemoglobin; predictors; operative time
1. Introduction
Lumbar spine fusion is a common surgical procedure used for the treatment of many spinal
conditions including those of a degenerative nature. Demand for spinal fusion presented a significant
volume increase in operative neurosurgery over the last decades, with a 220% rise in the 1990s and a
further increase of 12,000 procedures per year in the United States in the 2000s [1–3].
Unfortunately, significant blood loss remains a major concern in spine surgery, with a reported
volume loss ranging from 0.65 to 2.1 liters per case [4–9]. Thus, lumbar spine fusion has been recognized
to be among the top 10 surgical procedures that necessitate blood transfusion, with a rate that increased
from 4% to 8% in the United States from 2000 to 2009, and further up to 18% in many instances during
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the most recent years [10–12]. Excessive blood loss may require allogenic blood transfusion in order to
avoid morbidities, i.e., hypotension and hypoperfusion with cardiac, pulmonary, and renal damage,
as well as coagulopathy [9]. Nevertheless, blood transfusion has been reported to be associated with
higher risk of the development of wound infections, venous thromboembolism, pulmonary embolism,
myocardial infarction, and with longer hospital length of stay (LOS), besides having a variable cost per
unit transfused [12,13].
Several studies have documented the variables associated with the need for blood transfusion in
spine surgery, which include both patient-specific, i.e., age, gender, comorbidities, and surgery-related
factors, i.e., operative time, multilevel procedures, deformity corrections [3,14]. Identifying factors
associated with perioperative blood transfusion would allow for the early recognition of patients at
greatest risk, and might improve current transfusion practice, leading to a more appropriate blood
products allocation. However, no comprehensive studies characterizing the need for blood transfusion
specifically on elective primary posterior lumbar fusion in centers of excellence for spine surgery
are available. Thus, the purpose of this study was to retrospectively evaluate the perioperative
blood transfusion need in patients undergoing elective primary lumbar posterior spine fusion and to
determine predictors for red blood cell (RBC) transfusion in a high-volume center for spine surgery
with approximately more than 650 procedures per year, half of which are at the lumbar level.
2. Material and Methods
2.1. Study Design, Setting, and Selection of Participants
The study was a retrospective cohort study in which the RBC transfusion ratio was evaluated in
patients undergoing elective surgery for primary posterior lumbar spine fusion in the Neurosurgery I
operative unit (O.U.), Neuro Center, at Humanitas Research hospital, Rozzano, Milan, Italy, over a
period of 3 consecutive years between 1 January 2014 and 31 December 2016. The study was approved
by the Institutional Review Board. At the time of hospital admission, each patient provided informed
consent for the use of the data for research purposes. All patients undergoing elective surgery for
lumbar spine fusion were included in the analyses. Patients admitted for urgent surgery (not elective)
and/or with a previous lumbar fusion and/or with metastatic spine disease as cause for the surgery
were excluded from the analyses. This was because these conditions are known to be associated with a
higher risk of intraoperative bleeding [5].
2.2. Data Collection, Processing, and Outcomes
At the Humanitas Research hospital, all clinical data are prospectively collected and stored
electronically in the data management system (Hospital, Lutech, Italy) in order to be retrieved at
any time for clinical and research purposes. A retrospective database analysis was performed to
identify all patients who underwent posterior lumbar spine fusion. Patients were identified using
the Institutional procedural terminology code “8108” corresponding to surgery of posterior lumbar
spine fusion. Screening of the electronic medical records to identify patients meeting inclusion
criteria was performed by a medical doctor (GR) and an administrative responsible (DT). Patients’
demographics (age, gender, body mass index (BMI)), comorbidities (i.e., arterial hypertension, diabetes,
ischemic cardiomyopathy, chronic use of anticoagulant/antiplatelet drugs) and American Society
of Anesthesiologists (ASA) class, laboratory results (i.e., hemoglobin (HB), hematocrit (HCT) and
coagulation parameters), occurrence and quantity (number of units) of RBC transfusion, operative
time, and LOS, were retrieved for analysis. The coagulation parameters included platelets (PLT),
partial prothrombin time (PTT), and international normalized ratio (INR). HB data were collected
before the surgery, after completion of the surgery (day 0), and at 1, 2 and 3 days later. The main
outcome was the occurrence of perioperative RBC transfusion, defined as any patient requiring at least
1 unit of RBC from the time of surgery up to hospital discharge.
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2.3. Statistical Analysis
Categorical variables are presented as numbers and proportions, while continuous variables
as median with interquartile range (IQR). Baseline characteristics by outcome occurrence
(RBC transfusion) were compared by Chi-Square in case of categorical variables or by the
non-parametric Mann–Whitney test for continuous non-normally distributed data. HB level changes
over time were analyzed using the Wilcoxon signed rank test for paired data. Multivariable logistic
regression was used to identify baseline factors that were predictors of RBC transfusion. All variables
associated with the transfusion in the univariate analysis (p < 0.05) were included in the multivariable
model. Odds ratios (OR) with the corresponding 95% CI were calculated and p values were considered
statistically significant if they were less than 0.05. Prognostic accuracy of variables associated with
the need for transfusion was evaluated by receiver operating characteristic curve (ROC) analyses
and compared with Delong test. All statistical analyses were performed MedCalc Statistical Software
version 17.7.2 (MedCalc Software bvba, Ostend, Belgium).
3. Results
During the three years of observation, among the 6711 patients admitted to the O.U. Neurosurgey I,
5560 underwent a surgical procedure, 1951 of which were for spine fusion. Nine hundred-forty-eight
of the above spine surgeries were specifically for posterior lumbar fusion and 874 of them were elective
primary fusions (Figure 1). None of the patients underwent preoperative autologous blood donation
nor intraoperative blood collection (Cell Saver). The majority of patients were female with a median
age of 66 years and an ASA class of 2. Half of the patients presented a history of arterial hypertension,
while lesser than 10% had diabetes and/or a previous ischemic cardiomyopathy. Sixteen percent of
patients were assuming an anticoagulant/platelet therapy chronically, which was interrupted during
the week prior to the surgery (Table 1). The median operative time was approximately 2 h. Pre-surgery
HB was 14 g/dL; it then decreased of 2.6 g/dL during the first day after the surgery and of almost
5 g/dL after 3 days (Table 1).
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Table 1. Whole population description.
Population, n 874
Age, year 66 (56–73)
Male, n (%) 333 (38)
BMI, kg/m2 26 (23–29)
Comorbities, n (%)
Ischemic cardiomyopathy 42 (5)
Arterial hypertension 421 (49)
Diabetes 82 (10)
Use of anticoagulant/antiplatelet drugs 138 (16)
ASA, class 2 (1–2)
HB pre-surgery, g/dL 14 (13.1–14.9)
HCT pre-surgery, % 42 (40–45)
INR pre-surgery, ratio 1 (0.96–1.04)
PTT pre-surgery, ratio 1.01 (0.95–1.07)
Platelets, n*103/mm3 232 (198–270)
Operative time, min 117 (96–140)
HB on day 0 after surgery, g/dL 11.6 (10.7–12.7) *
HB on day 1 after surgery, g/dL 11.4 (10.4–12.4) *§
HB on day 2 after surgery, g/dL 10.3 (9.4–11.2) *§
HB on day 3 after surgery, g/dL 9.2 (8.6–10.1) *§
Transfused patients, n (%) 54 (6)
LOS, day 4 (4–5)
Data are reported as median (interquartile) BMI, body mass index; ASA, American Society of Anesthesiologists
classification; HB, hemoglobin; HCT, hematocrit; INR, International normalized ratio (prothrombin time); PTT,
partial thromboplastin time; LOS, length of stay.* p < 0.01 vs. HB pre-surgery; § p < 0.01 vs. HB in the preceding day.
Among the 874 patients undergoing elective primary posterior lumbar spine fusion, only 54 (6%)
required RBC transfusion, which occurred on average on day 2 (1–3) after surgery. No difference in the
surgical procedures, i.e., number of spinal segments instrumented and technique (all the procedures
were “open”) were observed between the transfused and the non-transfused patients. Eighty-three
percent of the transfused patients were female compared to the 60% of the non-transfused ones
(p = 0.0008). Moreover, the transfused patients were older and had a higher ASA grade (p = 0.0002),
with a significantly more frequent history of diabetes and use of anticoagulant/antiplatelet drugs,
compared to the non-transfused ones (Table 2). Patients undergoing RBC transfusion presented
a pre-surgery HB and HCT values significantly lower compared to those who did not receive the
transfusion (p < 0.0001, Table 2). After surgery, the HB levels decreased in all patients (Table 1);
however, in the transfused patients, the HB levels were consistently significantly lower compared to
the non-transfused ones, already after completion of the surgery (9.9 g/dL vs. 12.1 g/dL, p < 0.0001)
and during the subsequent 3 days (p < 0.0001, Table 2). At the moment of transfusion, median HB was
7.8 g/dL, and patients received a median of 2 RBC units.
Table 2. Comparison between transfused and not transfused patients.
Transfused
(n = 54)
Not Transfused
(n = 820) p Value
Male, n (%) 9 (17) 324 (40) 0.00
Age, year 71 (63–74) 66 (55–73) <0.01
BMI, kg/m2 25 (23–28) 26 (23–29) 0.22
Comorbities, n (%)
Ischemic cardiomyopathy 4 (8) 38 (5) 0.34
Arterial hypertension 29 (56) 392 (49) 0.34
Diabetes 11 (20) 71 (9) 0.01
Use of anticoagulant/antiplatelet drugs 14 (26) 124 (16) 0.04
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Table 2. Cont.
Transfused
(n = 54)
Not Transfused
(n = 820) p Value
ASA, class 2 (2–3) 2 (1–2) 0.00
HB pre-surgery, g/dL 12.7 (11.3–13.3) 14 (13.2–14.9) <0.01
HCT pre-surgery, % 38 (35–40) 43 (40–45) <0.01
INR pre-surgery, ratio 1 (0.95–1.04) 1 (0.96–1.04) 0.98
PTT pre-surgery, ratio 0.99 (0.94–1.06) 1.01 (0.95–1.07) 0.43
Platelets, n*103/mm3 235 (203–266) 232 (198–270) 0.88
Operative time, min 133 (114–151) 117 (95–139) 0.00
HB on day 0 after surgery, g/dL 9.9 (9.2–10.8) * 12.1 (11.2–13.1) * <0.01
Hb on day 1 after surgery, g/dL 9.1 (8.8–9.9) *§ 11.5 (10.6–12.4) *§ <0.01
HB on day 2 after surgery, g/dL 8.3 (7.8–9.1) *§ 10.4 (9.6–11.4) *§ <0.01
HB on day 3 after surgery, g/dL 8.5 (7.9–9.6) *# 9.4 (8.7–10.3) *§ <0.01
HB at transfusion, g/dL 7.8 (7.4–7.9) * N.A. N.A.
RBC units transfused, n 2 (2–2) N.A. N.A.
LOS, day 6 (5–7) 4 (4–5) <0.01
Data are reported as median (interquartile); comparisons performed with 2-tail Mann-Whitney test. BMI, body
mass index; ASA, American Society of Anesthesiologists classification; HB, hemoglobin; HTC, hematocrit; INR,
International normalized ratio (prothrombin time); PTT partial thromboplastin time; RBC, packed red blood cell;
LOS, length of stay. * p < 0.01 vs. HB pre-surgery; # p < 0.05 and § p < 0.01 vs. HB in the preceding day.
The univariate odds ratios for prediction of RBC transfusion are reported in Table 3. Female
gender, older age, higher ASA grade, presence of diabetes, use of anticoagulant/platelet drugs prior
to the surgery, longer operative time, and lower pre-surgery HB level, were associated with the need
for RBC transfusion. However, in the multivariate logistic regression, only a lower pre-surgery HB
level (OR (95% CI) 2.84 (2.11–3.82), per 1 g/dL decrease), a higher ASA class (1.77 (1.03–3.05), per 1
grade increase) and a longer operative time (1.02 (1.01–1.02), per 1 min increase) were independently
associated with the need for transfusion (Table 3).
Table 3. Univariate and multivariable logistic regression models for prediction of red blood
cells transfusion.
Univariate Multivariable
OR 95% CI p Value OR 95% CI p Value
Gender, female 3.266 1.575–6.772 0.01 1.342 0.554–3.249 0.52
Age 1.037 1.009–1.066 0.01 1.022 0.986–1.059 0.24
HB pre-surgery 2.937 2.231–3.865 <0.01 2.838 2.108–3.820 <0.01
ASA class 2.431 1.527–3.870 0.00 1.773 1.032–3.046 0.04
Presence of diabetes 2.627 1.297–5.319 0.01 1.625 0.660–3.999 0.29
Use of anticoag/platelets 1.908 1.032–3.54 0.05 1.713 0.782–3.754 0.18
Operative time 1.014 1.007–1.021 0.00 1.016 1.007–1.024 0.00
OR, odds ratio; ASA, American Society of Anesthesiologists classification; HB, hemoglobin.
The AUC of the ROC curves for prediction of RBC transfusion were: 0.63 for ASA grade
(p = 0.0002); 0.67 for operative time (p < 0.0001); and 0.82 (p < 0.0001) for pre-surgery HB (p = 0.0001
vs. ASA class and p = 0.0004 vs. operative time) (Figure 2). The balanced cut off levels (sensitivity
(Sn)/specificity (Sp)) for prediction of RBC transfusion were: 2 (Sn. 0.3/Sp. 0.9) for ASA class; 112 min
(Sn. 0.8/Sp. 0.5) for operative time; and 13.3 g/dL (Sn. 0.8/Sp.0.7) for pre-surgery HB.
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Figure 2. Receiver operator curves (ROC) and area under the curves (AUC) for pre-surgery hemoglobin
(HB), American Society of Anesthesiologists (ASA) classification, and operative time for prediction of
perioperative red blood cells transfusion.
The LOS was in median 4 days in the whole population (Table 1). However, LOS was significantly
longer in patients who received RBC transfusion compared to those not transfused (p < 0.0001, Table 2).
RBC transfusion had an OR (95% CI) in predicting longer LOS of 8.04 (3.594–18.013) (p < 0.0001). In a
multivariate model, adjusted for age, gender, BMI, ASA class, and operative time, being transfused
was independently associated with longer LOS (OR (95% CI) 7.536 (2.925–19.410), p < 0.0001).
4. Discussion
This retrospective study demonstrated that in the instance of elective surgery for primary posterior
lumbar fusion in a high-volume center for spine surgery, incidence of RBC transfusion was low,
occurring in 1 patient every 16.5. Indeed, only 54 patients were transfused, over 874 undergoing elective
surgery in a three-year period. Higher ASA class, longer operative time, and lower pre-surgery HB
level were independent predictors of the need for perioperative transfusion. Finally, RBC transfusion
was significantly associated with longer LOS.
Patients undergoing major spine surgery can experience significant intraoperative blood loss,
with hemorrhage rates reported to be as high as 50 to 80% in adult patients [15,16]. Several factors
may contribute to a direct blood loss, i.e., exposure of cancellous bone, stripping of skeletal muscles,
extensive spinal instrumentation, transpedicular vertebrectomy, staged anterior-posterior approaches,
and to an indirect blood loss, i.e., due to hypervascularization, altered blood coagulation profile,
operative time, and intraoperative arterial hypertension [6,7,14,17,18].
The incidence of blood transfusion after spine surgery is quite variable and can be as high
as 30% [12]. Considering specifically the lumbar fusion, in the Nationwide Inpatient Sample
database, including data from approximately 1000 hospitals in the United States, an incidence of
blood transfusion of 11% was reported in more than 1 million patient data analyzed over a period
of six years) [19]. In the American College of Surgeons National Surgical Quality Improvement
Program (ACS-NSQIP), another United States database which captures data from over 400 participating
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hospitals, among the 4223 primary posterior lumbar fusion procedures over a period of three years,
16.7% required blood transfusion [4]. Similarly, in the nationwide Canadian network, 18% of the
772 patients undergoing posterior lumbar fusion over an eight-year period had blood transfusion [20].
In our O.U. we observed a lower incidence of RBC transfusion, which occurred in only 6% of
874 patients subjected to elective surgery. Such a low incidence may be explained as a consequence
of the much higher volume of spinal procedures performed in our O.U., having achieved more
than 700 cases per year, in comparison to a rate ranging from 4 to 167 cases per year in the above
National databases, which included a variety of low, middle, and high hospital caseloads [4,19,20].
Likely, the high rate of spine surgeries per year in our O.U. accounted for a continuous procedure
optimization with concurrent complications reduction. In addition, in our analyses, only elective
primary lumbar fusion mainly due to degenerative spine disease, i.e., spondylolisthesis, were included,
excluding urgent procedures due to trauma, cases due to metastatic spinal tumor, and revisions of a
previous lumbar fusion—conditions known to be associated with at least a three-fold higher risk of
massive bleeding, due to either a tumor-related hypervascularization and/or more extensive spinal
instrumentations [5,21,22].
In accordance with earlier reports, in our population, factors associated with perioperative
blood transfusion were older age, female gender, higher ASA grade, presence of diabetes, use of
anticoagulant/platelet drugs, longer operative time, and low pre-surgery HB levels. However,
in the multivariate model, only ASA grade, operative time, and pre-surgery HB were confirmed as
independent predictors of RBC transfusion [4,12,19,20]. Thus, it has been reported that older patients
were more likely to receive a blood transfusion than middle-aged patients and that as the number of
comorbidities increased, the probability of blood transfusion increased as well [12,19]. When patients
had more than 85 years and four or more comorbidities, a triple risk to receive blood transfusion
has been described [19]. Similarly, an ASA score ≥2 or ≥3 had up to 6 or 18-fold greater probability
to receive blood transfusion respectively, compared to a score <2 or <3 [12,19,20,23]. Indeed, in our
population, an age >66 years accounted for a 2.1-fold higher risk of blood transfusion, and the need for
RBC transfusion increased of 77% for each unit increase in the ASA grade, accounting overall for a
2.3-fold higher incidence of transfusion for an ASA >2. These relationships have been explained by the
concurrent presence of comorbidities in aged patients, for which physicians prefer to maintain higher
HB levels in order to improve oxygen delivery to the tissues [24,25]. However, this was not the case in
our population, since the median HB was already 7.8 g/dL at the time of transfusion. The greater use
of medications interfering with coagulation or platelet function in aged people with comorbidities has
been hypothesized as an additional explanation [24,25]. Indeed, our data confirmed past research that
suggested such treatments significantly increased the risk of bleeding, either intraoperatively and/or
from postoperative blood drainages, in patients undergoing lumbar fusion, despite discontinuation of
therapy at least 1 week preoperatively [26–28].
Extended surgical time has been also previously associated with transfusion requirements
following primary lumbar fusion, with an increase in the odds of transfusion of 4.2% for each 60-min
increase, probably related to a greater complexity of the procedures, with extensive bone exposure and
instrumentation [4–7,12,14,17–20]. This relationship was confirmed in our large population, in which
the need for blood transfusion increased by almost 1.6% for each minute of surgery, leading to almost
a three-fold rise for procedures lasting more than 2 h.
Among all the factors associated with the need for perioperative blood transfusion in our
population, pre-surgery HB level, however, has appeared as the most predictive one. Indeed, a 2.8-fold
increase in the risk to receive an RBC transfusion was observed for each 1 g/dL decrease in HB, and
a pre-surgery HB <13.3 g/dL accounted for an odds for transfusion of 6.7. This predictive value of
13.3 g/dL is quite similar to that of 13.6 earlier reported in a smaller population [23]. Likely, pre-surgery
HB levels can be also involved in the higher requirement of RBC transfusion in females, who are
known to be more inclined to anemia [19]. In our population, in fact, the female gender was associated
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with a higher incidence of blood transfusion only in the univariate model, but the association was lost
in the multivariate one.
Indeed, preoperative anemia, together with the amount of perioperative HB drop, were shown to
be independent risk factors for increased morbidity, mortality, and longer LOS, with overall increased
healthcare costs [4,6,12,29–33]. Thus, the goal for an optimal pre-surgery patient’s preparation would be
to detect a condition of anemia or borderline HB levels as early as possible before the scheduled surgery
in order to provide correction with treatments directed to increase the RBC mass, i.e., administration
of iron, vitamin B12, folic acid, and erythropoietin [34–36]. Optimizing the RBC mass before the spine
surgery may be a pillar for an optimized patient blood management. However, even if preoperative
anemia is adequately corrected prior to surgery, there is still the risk of massive bleeding during spine
surgery. In these instances, antifibrinolytic drugs have been used efficiently to decrease perioperative
blood loss, up to 49%, and transfusion requirements, up to 80% in some instances [37–39].
Thus, at the time of patient’s preparation to the surgery, paying attention to factors associated
with the need for perioperative blood transfusion, like the ones emerged from our study, i.e., ASA class,
expected operative time, and baseline HB level, may provide guidance to determine which patients
will benefit from preoperative optimization of the RBC mass, and in the planning for perioperative
invasive monitoring, intravenous access, blood product availability, and eventually administration
of anti-fibrinolytics [14,40]. Efforts to minimize perioperative administration of blood products
might decrease the costs associated with blood transfusion that range between 700–1200 US dollars
for administration of one RBC unit, plus additional costs up to 1000 US dollars for treatment of
associated side effects [13,41,42]. Indeed, when high-risk patients were identified and an optimization
protocol was initiated, a significant reduction in perioperative transfusions was reported, with a cost
of approximately 850 US dollars, which represented a clearly favorable approach as it was still cheaper
than one unit of RBC and its side effects [36,40]. Another interventional cohort study demonstrated
that within 1 year from the introduction of a program of patient blood management, transfusions of all
allogeneic blood products per 1000 patients was reduced by 27% with a cost reduction of over 2 million
US dollars on a hospital level [42]. In our O.U., the overall cost for RBC transfusion in the 54 patients
over the three years of observation amounted to approximately 28,000 euros without considering other
costs related to the longer LOS and treatment of complications.
We need to acknowledge several limitations in the interpretation of our findings. First, this was
a single-center retrospective study and thus a selection bias is present. Nevertheless, all patients
undergoing elective primary posterior lumbar spine fusion were included in the analyses. Moreover,
the large number of patients included and the high-quality data have advantages that outweigh
this limitation. Indeed, our O.U. presented a high-volume of spine fusion surgeries, such that our
population may be considered sufficiently representative to make results translatable to other centers.
Second, we did not report the amount of perioperative bleeding; however, we have included data on
HB from day 0, at the end of the surgery, and then daily up to day 3 after the surgery. Finally, we did not
evaluate additional preventive measures to decrease the intraoperative bleeding, i.e., anti-fibrinolytic
therapy, although these might have occasionally occurred during high-risk spinal procedures.
5. Conclusions
This retrospective study demonstrated that in the instance of elective surgery for primary posterior
lumbar fusion in a high-volume center for spine surgery, incidence of red blood cell transfusion was
low, occurring in 1 patient every 16.5. Higher American Society of Anesthesiologists class, longer
operative time, and lower pre-surgery hemoglobin level, were independent predictors for the need of
perioperative red blood cell transfusion. Finally, a low pre-surgery hemoglobin level was the most
significant predictor of perioperative red blood cell transfusion.
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